Vaxxinity has joined TransCelerate BioPharma as the first emerging biotechnology organization of the trailblazing consortium that is accelerating and simplifying the research and development of innovative new therapies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VAXX:
- Vaxxinity Joins TransCelerate Research and Development Consortium
- Vaxxinity announces first subjects dosed in Phase 1 trial of VXX-401
- Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
- Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
- Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida